Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase- and B-Raf Proto-Oncogene-Wildtype Epithelioid Glioblastoma

World Neurosurg. 2019 Jul:127:213-215. doi: 10.1016/j.wneu.2019.04.025. Epub 2019 Apr 8.

Abstract

We here report findings on magnetic resonance imaging from a 60-year-old patient with an epithelioid glioblastoma of the corpus callosum treated with radiotherapy in combination with concomitant and adjuvant temozolomide. Neuropathology revealed a highly aggressive molecular subtype of the epithelioid glioblastoma without an isocitrate dehydrogenase and B-Raf proto-oncogene mutation or a O6-methylguanine-DNA-methyltransferase promoter hypermethylation. This subtype is typically associated with an unfavorable clinical course and poor overall survival. Unexpectedly, the first follow-up magnetic resonance imaging 10 weeks after chemoradiation completion revealed an early and almost complete treatment response.

Keywords: Brain tumors; Chemoradiation; Glioma; Neuroimaging; Temozolomide.

Publication types

  • Case Reports

MeSH terms

  • Brain Neoplasms / diagnostic imaging*
  • Brain Neoplasms / therapy*
  • Chemoradiotherapy / methods
  • Epithelioid Cells / pathology
  • Fatal Outcome
  • Glioblastoma / diagnostic imaging*
  • Glioblastoma / therapy*
  • Humans
  • Isocitrate Dehydrogenase* / genetics
  • Magnetic Resonance Imaging / trends
  • Male
  • Middle Aged
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins B-raf* / genetics
  • Treatment Outcome

Substances

  • MAS1 protein, human
  • Proto-Oncogene Mas
  • Isocitrate Dehydrogenase
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf